Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma

被引:14
作者
Cohen, Jonathon B. [1 ]
Ruppert, Amy S. [1 ]
Heerema, Nyla A. [1 ,2 ]
Andritsos, Leslie A. [1 ]
Jones, Jeffrey A. [1 ]
Porcu, Pierluigi [1 ]
Baiocchi, Robert [1 ]
Christian, Beth A. [1 ]
Byrd, John C. [1 ]
Flynn, Joseph [1 ]
Penza, Sam [1 ]
Devine, Steven M. [1 ]
Blum, Kristie A. [1 ]
机构
[1] Ohio State Univ, James Comprehens Canc Ctr, Div Hematol, Columbus, OH 43210 USA
[2] Ohio State Univ, James Comprehens Canc Ctr, Dept Pathol, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
Cytogenetics; del(17p); Non-Hodgkin lymphoma; Outcomes; Prognosis; INTERNATIONAL PROGNOSTIC INDEX; CHRONIC LYMPHOCYTIC-LEUKEMIA; HIGH-DOSE THERAPY; CYTOGENETIC ANALYSIS; RANDOMIZED-TRIALS; RESPONSE CRITERIA; IMMUNOCHEMOTHERAPY; TRANSPLANTATION; ABERRATIONS; CANCER;
D O I
10.1016/j.clml.2014.12.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We evaluated the role of pretreatment cytogenetics in patients with untreated mantle cell lymphoma (MCL). Patients with >= 3 chromosomal abnormalities had inferior progression-free and overall survival and had more high-risk clinical features. The effect of cytogenetics merits further evaluation in prognostic assessment in MCL. Background: Pretreatment cytogenetics are not routinely used to predict patient outcomes in mantle cell lymphoma (MCL). Based on the prognostic utility of cytogenetics in other diseases, we reviewed the effect of a complex karyotype (CK) in MCL. Patients and Methods: We included patients evaluated between November, 2002, and May, 2011. Those with >= 3 chromosomal abnormalities on a pre-treatment cytogenetic evaluation were defined as CK. Demographic, clinical, and survival differences between patients with OK and non-CK (NCK) were assessed. Results: Of 80 patients, 32 (40%) had CK, which was associated with high-risk clinical risk factors. Therapy did not differ between the groups, nor did rate of autologous stem cell transplant (ASCT). The 2-year progression-free survival (PFS) estimates were 70% and 48% for patients with NCK and OK, respectively (P = .02). Two-year overall survival (OS) estimates were also greater in those with NCK versus CK (85% vs. 58%; P = .02). When controlling for high-risk Mantle Cell Lymphoma International Prognostic Index (MIPI) score (P = .006), bulky disease (P = .01), and ASCT in first remission (P = .01), CK was not significantly associated with PFS (P = .18). Conclusion: CK is associated with shortened PFS and OS in MCL but has not been demonstrated to be prognostic independent of other variables in this series. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:278 / 285
页数:8
相关论文
共 26 条
[1]   Cytogenetic analysis in mantle cell lymphoma: A review of 214 cases [J].
Au, WY ;
Gascoyne, RD ;
Viswanatha, DS ;
Connors, JM ;
Klasa, RJ ;
Horsman, DE .
LEUKEMIA & LYMPHOMA, 2002, 43 (04) :783-791
[2]   Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine [J].
Blum, William ;
Garzon, Ramiro ;
Klisovic, Rebecca B. ;
Schwind, Sebastian ;
Walker, Alison ;
Geyer, Susan ;
Liu, Shujun ;
Havelange, Violaine ;
Becker, Heiko ;
Schaaf, Larry ;
Mickle, Jon ;
Devine, Hollie ;
Kefauver, Cheryl ;
Devine, Steven M. ;
Chan, Kenneth K. ;
Heerema, Nyla A. ;
Bloomfield, Clara D. ;
Grever, Michael R. ;
Byrd, John C. ;
Villalona-Calero, Miguel ;
Croce, Carlo M. ;
Marcucci, Guido .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (16) :7473-7478
[3]   Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation [J].
Budde, Lihua E. ;
Guthrie, Katherine A. ;
Till, Brian G. ;
Press, Oliver W. ;
Chauncey, Thomas R. ;
Pagel, John M. ;
Petersdorf, Steven H. ;
Bensinger, William I. ;
Holmberg, Leona A. ;
Shustov, Andrei R. ;
Green, Damian J. ;
Maloney, David G. ;
Gopal, Ajay K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3023-3029
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[6]   Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 [J].
Damon, Lloyd E. ;
Johnson, Jeffrey L. ;
Niedzwiecki, Donna ;
Cheson, Bruce D. ;
Hurd, David D. ;
Bartlett, Nancy L. ;
LaCasce, Ann S. ;
Blum, Kristie A. ;
Byrd, John C. ;
Kelly, Michael ;
Stock, Wendy ;
Linker, Charles A. ;
Canellos, George P. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6101-6108
[7]   Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group [J].
Determann, Olaf ;
Hoster, Eva ;
Ott, German ;
Bernd, Heinz Wolfram ;
Loddenkemper, Christoph ;
Hansmann, Martin Leo ;
Barth, Thomas E. F. ;
Unterhalt, Michael ;
Hiddemann, Wolfgang ;
Dreyling, Martin ;
Klapper, Wolfram .
BLOOD, 2008, 111 (04) :2385-2387
[8]  
Dohner H, 1997, LEUKEMIA, V11, pS19
[9]   Incidence and Prognostic Impact of Secondary Cytogenetic Aberrations in a Series of 145 Patients with Mantle Cell Lymphoma [J].
Espinet, Blanca ;
Salaverria, Itziar ;
Bea, Silvia ;
Ruiz-Xiville, Neus ;
Balague, Olga ;
Salido, Marta ;
Costa, Dolors ;
Carreras, Joaquim ;
Eugenia Rodriguez-Vicente, Ana ;
Luis Garcia, Juan ;
Maria Hernandez-Rivas, Jesus ;
Jose Calasanz, Maria ;
Siebert, Reiner ;
Ferrer, Ana ;
Salar, Antonio ;
Carrio, Ana ;
Polo, Natividad ;
Antonio Garcia-Marco, Jose ;
Domingo, Alicia ;
Gonzalez-Barca, Eva ;
Romagosa, Vicenc ;
Marugan, Isabel ;
Lopez-Guillermo, Armando ;
Milla, Fuensanta ;
Luis Mate, Jose ;
Luno, Elisa ;
Sanzo, Carmen ;
Collado, Rosa ;
Oliver, Isabel ;
Monzo, Sebastia ;
Palacin, Antonio ;
Gonzalez, Teresa ;
Sant, Francesc ;
Salinas, Ramon ;
Teresa Ardanaz, Maria ;
Font, Llorenc ;
Escoda, Lourdes ;
Florensa, Lourdes ;
Serrano, Sergi ;
Campo, Elias ;
Sole, Francesc .
GENES CHROMOSOMES & CANCER, 2010, 49 (05) :439-451
[10]   Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia:: results from Cancer and Leukemia Group B 8461 [J].
Farag, Sherif S. ;
Archer, Kellie J. ;
Mrozek, Krzysztof ;
Ruppert, Amy S. ;
Carroll, Andrew J. ;
Vardiman, James W. ;
Pettenati, Mark J. ;
Baer, Maria R. ;
Qumsiyeh, Mazin B. ;
Koduru, Prasad R. ;
Ning, Yi ;
Mayer, Robert J. ;
Stone, Richard M. ;
Larson, Richard A. ;
Bloomfield, Clara D. .
BLOOD, 2006, 108 (01) :63-73